Ventyx Biosciences Q2 FY25 Revenue $5.4mln, Cash Balance $209mln.

• Ventyx Biosciences reports Q2 2025 financial results • Positive Phase 2a biomarker data for Parkinson's disease treatment • Phase 2 study of VTX2735 in recurrent pericarditis expected in Q4 2025 • Phase 2 study of VTX3232 in obesity and cardiometabolic risk factors fully-enrolled • Expected topline data in early Q4 2025 • Cash balance of $209M, expected to fund operations into at least H2 2026

Ventyx Biosciences, Inc. (Nasdaq: VTYX) recently reported its second-quarter 2025 financial results, highlighting significant progress in its pipeline and business operations. The company, focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, reported a cash balance of $209.0 million as of June 30, 2025, sufficient to fund planned operations into at least the second half of 2026.

The quarter also saw positive topline Phase 2a biomarker data for VTX3232, a central nervous system (CNS)-penetrant NLRP3 inhibitor, positioning it as a potential disease-modifying therapy for patients with Parkinson’s disease. The Phase 2a study met its primary objectives, demonstrating safety, tolerability, and potent suppression of NLRP3-related biomarkers in cerebral spinal fluid (CSF) and plasma. Additionally, VTX3232 showed improvements in motor and non-motor symptoms of Parkinson’s disease, as measured by the MDS-UPDRS.

Ventyx also announced that its Phase 2 study of VTX2735 in recurrent pericarditis is expected to release topline data in Q4 2025. The ongoing Phase 2 trial is evaluating VTX2735, a peripherally restricted NLRP3 inhibitor, in patients with recurrent pericarditis. The study aims to assess safety, change in pain score, and change in high-sensitivity C-reactive protein (hsCRP) levels.

Furthermore, the Phase 2 study of VTX3232 in participants with obesity and cardiometabolic risk factors is fully-enrolled and on track to yield topline data in early Q4 2025. This trial aims to assess safety and change in hsCRP levels, with additional exploratory endpoints to guide future development in cardiometabolic diseases.

Raju Mohan, PhD, President and Chief Executive Officer of Ventyx Biosciences, commented, “We continue to make significant progress in our pipeline, with promising data from our Phase 2a trial of VTX3232 in Parkinson’s disease and our ongoing studies in recurrent pericarditis and cardiometabolic diseases. We remain committed to our mission of developing innovative oral therapies for patients with high unmet medical needs.”

Financial Highlights:
- Cash, cash equivalents, and marketable securities: $209.0 million
- Research and Development (R&D) expenses: $22.3 million (Q2 2025), compared to $27.8 million (Q2 2024)
- General and Administrative (G&A) expenses: $7.1 million (Q2 2025), compared to $7.9 million (Q2 2024)
- Net loss: $27.0 million (Q2 2025), compared to $32.0 million (Q2 2024)

References:
[1] https://www.morningstar.com/news/globe-newswire/9508489/ventyx-biosciences-reports-second-quarter-2025-financial-results-and-highlights-recent-corporate-progress